New Data is Presented on Investigational Oral Anticoagulant Apixaban in Acute Coronary Syndrome Patients

Original Source

Bristol-Myers Squibb to Hold Investor Teleconference to Discuss ESC Highlights

Original Source

Bristol-Myers Squibb to Hold Investor Teleconference to Discuss ESC Highlights

Original Source

Bristol-Myers Squibb to Hold Investor Teleconference to Discuss ESC Highlights

Original Source

Bristol-Myers Squibb and Pfizer Provide Update on Apixaban Clinical Development Program

Original Source

Bristol-Myers Squibb and PDL BioPharma Enter Global Alliance to Develop Novel Treatment for Multiple Myeloma

Original Source

Bristol-Myers Squibb and PDL BioPharma Enter Global Alliance to Develop Novel Treatment for Multiple Myeloma

Original Source

Bristol-Myers Squibb and PDL BioPharma Enter Global Alliance to Develop Novel Treatment for Multiple Myeloma

Original Source

Bristol-Myers Squibb and PDL BioPharma Enter Global Alliance to Develop Novel Treatment for Multiple Myeloma

Original Source

NJ, CT, NY & MD School Districts Join Program That Teaches High School Students How Medicines Are Made

Original Source

CORRECTING and REPLACING CASTLE Data Showed Boosted REYATAZ(R) (atazanavir sulfate) and Lopinavir/r Achieved Similar Results for Undetectable Viral Load in Treatment-Naive HIV-1 Infected Patients, Regardless of Gender

Original Source

CORRECTING and REPLACING CASTLE Data Showed Boosted REYATAZ(R) (atazanavir sulfate) and Lopinavir/r Achieved Similar Results for Undetectable Viral Load in Treatment-Naive HIV-1 Infected Patients, Regardless of Gender

Original Source

CORRECTING and REPLACING CASTLE Data Showed Boosted REYATAZ(R) (atazanavir sulfate) and Lopinavir/r Achieved Similar Results for Undetectable Viral Load in Treatment-Naive HIV-1 Infected Patients, Regardless of Gender

Original Source

CORRECTING and REPLACING CASTLE Data Showed Boosted REYATAZ(R) (atazanavir sulfate) and Lopinavir/r Achieved Similar Results for Undetectable Viral Load in Treatment-Naive HIV-1 Infected Patients, Regardless of Gender

Original Source

BRISTOL-MYERS SQUIBB LAUNCHES SECURE THE FUTURE(R) TECHNICAL ASSISTANCE PROGRAM TO OPTIMIZE COMMUNITY SERVICES FOR COMPREHENSIVE HIV MANAGEMENT IN SUB-SAHARAN AFRICA

Original Source

CASTLE Data Showed Boosted REYATAZ® (atazanavir sulfate) and Lopinavir/r Achieved Similar Results for Undetectable Viral Load in Treatment-Naive HIV-1 Infected Patients, Regardless of Gender

Original Source

CASTLE Data Showed Boosted REYATAZ® (atazanavir sulfate) and Lopinavir/r Achieved Similar Results for Undetectable Viral Load in Treatment-Naive HIV-1 Infected Patients, Regardless of Gender

Original Source

Bristol-Myers Squibb Announces Completion of ConvaTec Divestiture

Original Source

Bristol-Myers Squibb Announces Completion of ConvaTec Divestiture

Original Source

Bristol-Myers Squibb Announces Completion of ConvaTec Divestiture

Original Source

Notice: ob_end_flush(): failed to send buffer of zlib output compression (0) in /home/biznews/public_html/wp-includes/functions.php on line 5107